The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1450
ISSUE 1450
September 1, 2014
Issue 1450
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Statins and Diabetes Risk
September 1, 2014 (Issue: 1450)
In 2012, the FDA required manufacturers of HMG-CoA
reductase inhibitors (statins) to add a warning to their
labels about reports of increased blood glucose and
glycosylated hemoglobin (HbA1c) levels. Since then,
several new studies have been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.